Engineered Nanoparticles Hold Promise in Delivering Precision Cancer Treatments

McGill University researchers have built tiny particle carriers that can shuttle cancer drugs straight to diseased lymph nodes without touching healthy tissue, reducing toxic side effects in mice compared to conventional whole-body treatment. The method tackles cancer that has spread into the lymphatic system, a particularly tough stage that typically forces surgeons to remove affected nodes despite their essential role in coordinating immune responses throughout the body. 

Standard immunotherapy floods the bloodstream through IV infusion, activating immune responses indiscriminately across organs and tissues in ways that can grow dangerous enough to require dose cuts that weaken treatment. McGill Biomedical Engineering Assistant Professor Guojun Chen says certain immunotherapies trigger reactions so severe that doctors have no choice but to dial back dosing, undermining the drugs’ ability to fight cancer effectively. 

His team’s nanoparticles fix this problem by letting doctors deliver concentrated doses precisely to cancer sites while bypassing everything else, potentially cranking up therapeutic power while slashing the toxicity that limits how hard doctors can hit the disease. 

The particles act as molecular scouts, hunting for chemical signatures that cancerous lymph nodes pump out in high concentrations. When they spot these markers, the carriers pop open and dump their drug payload right there. Healthy tissue never flips the switch, so the medication stays locked down until natural cleanup processes flush it out without causing the collateral damage you get with traditional methods. 

Chen, who runs Canada Research Chair programs in Biomaterials and Biomacromolecule Delivery, says the particles basically wait for a specific molecular green light before releasing their contents. 

Testing in mice showed the engineered carriers cut harmful reactions while boosting treatment performance compared to conventional IV approaches that spray drugs everywhere. The technology attacks a stubborn clinical problem: doctors routinely cut out lymph nodes harboring cancer cells, but this removal guts organs the immune system needs for coordinated defense. 

Lead study author Yueyang Deng, a postdoctoral researcher in Chen’s lab at McGill, says the technique could hammer the cancer without torching the body’s natural defenses that healthy lymph nodes provide. 

The work shows how engineering is reshaping cancer treatment as materials science crashes into biology to produce new therapeutic approaches. Chen points to mRNA vaccines as proof of what nanomedicine can pull off when these fields team up, noting huge opportunities opening up as researchers keep connecting cancer biology with advanced materials. 

His group is running more animal safety tests before taking a shot at human trials. The research appeared in Proceedings of the National Academy of Sciences. It would be interesting to see whether these nanoparticles can be equipped to deliver some of the novel cancer treatments being developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI). 

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN